Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Growth in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the target of a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 259,720 shares, an increase of 88.8% from the June 30th total of 137,594 shares. Based on an average trading volume of 75,877 shares, the short-interest ratio is presently 3.4 days. Approximately 0.3% of the company’s shares are short sold.

Indaptus Therapeutics Stock Performance

Indaptus Therapeutics stock opened at $1.82 on Thursday. The stock’s 50 day moving average price is $2.70 and its 200 day moving average price is $2.36. The firm has a market capitalization of $206.10 million, a PE ratio of -0.12 and a beta of 1.11. Indaptus Therapeutics has a one year low of $0.92 and a one year high of $9.50.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.87) by $1.64.

Analysts Set New Price Targets

Several equities analysts recently weighed in on INDP shares. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

Institutional Investors Weigh In On Indaptus Therapeutics

A hedge fund recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is owned by institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.